Global Vaccine Particulate Adjuvants Market Growth 2026-2032
The global Vaccine Particulate Adjuvants market size is predicted to grow from US$ 1149 million in 2025 to US$ 1462 million in 2032; it is expected to grow at a CAGR of 3.5% from 2026 to 2032.
Vaccine Particulate Adjuvants are a class of adjuvants or adjuvant systems that exist as particles, colloids, vesicles, complexes, or other discrete micro- and nanostructures and are used to enhance vaccine immunogenicity, improve antigen delivery, and shape the quality of immune responses. They may appear as milky or translucent suspensions, colloidal dispersions, lyophilized powders, wet gels, or reconstituted particulate systems. Structurally, they commonly consist of inorganic salt particles, lipid bilayer vesicles, saponin-lipid complexes, virosomes, polymeric micro- or nanoparticles, or other biomimetic particulate carriers. Typical components include aluminum hydroxide, aluminum phosphate, cholesterol, phospholipids, saponins, monophosphoryl lipid A analogs, biodegradable polymers, and surface-functional excipients. Their mode of action is not limited to simple immune stimulation; rather, they adsorb, entrap, or co-deliver antigens in a particulate form that is more efficiently taken up by antigen-presenting cells. By tuning particle size, surface charge, rigidity, and interfacial chemistry, they promote cell recruitment at the administration site, lymph node trafficking, dendritic cell activation, and coordinated humoral and cellular immunity. Main categories include aluminum-salt particulates, liposomal adjuvants, virosomal adjuvants, ISCOM/ISCOMATRIX-type adjuvants, polymeric particle adjuvants, and other inorganic or biomimetic particulate adjuvants. Their major applications are in recombinant protein vaccines, subunit vaccines, conjugate vaccines, selected inactivated vaccines, therapeutic cancer vaccines, and veterinary vaccines.
Growth opportunities for Vaccine Particulate Adjuvants are primarily driven by changes in vaccine antigen platforms. Recombinant protein, subunit, conjugate, and many therapeutic vaccines are inherently less immunogenic and therefore more dependent on efficient delivery and immune amplification. Particulate systems are well positioned because they function both as carriers and as immune modulators. Mature aluminum-based systems will continue to provide the bulk of demand, while liposomes, ISCOM/Matrix-M, nano-alum, and polymeric particles are expected to gain share in elderly populations, immunologically weaker populations, and indications requiring stronger Th1 or cellular responses. The real opportunity for suppliers is not merely whether an adjuvant is present, but whether they can build scalable, stable, globally registrable adjuvant platforms compatible with new antigen formats. As RSV, malaria, shingles, broad influenza, therapeutic cancer vaccines, and next-generation veterinary vaccines advance, particulate systems that enable antigen sparing, durable immunity, cold-chain practicality, and differentiated protection profiles should continue to gain commercial importance.
The main restraints in this market are not conceptual novelty but scale-up, raw-material consistency, and regulatory comparability. Particulate adjuvants are highly sensitive to particle-size distribution, surface charge, adsorption capacity, reconstitution behavior, stability windows, and batch-to-batch reproducibility. Once a product moves from laboratory work into commercial manufacturing, the allowable process window narrows sharply. Aluminum salts are mature but offer limited differentiation, whereas liposomal and saponin-complex particles can provide stronger performance but demand tighter control of raw material purity, loading strategy, freeze-thaw stability, analytical methods, and supply-chain security. Critical inputs such as QS-21, MPL-like molecules, specialty lipids, and high-purity phospholipids may also be constrained by plant sourcing, licensing, purification routes, and global production footprint. For investors and industrial analysts, the central risk is to confuse ?works in research? with ?can be manufactured reproducibly at scale,? or to mistake a captive in-house vaccine adjuvant platform for an externally scalable commercial adjuvant business. Competition will therefore increasingly center on CMC, regulatory pathways, intellectual property, and manufacturing scale rather than preclinical efficacy alone.
Downstream demand is showing three clear trends. First, demand is expanding from traditional pediatric immunization into vaccines for older adults, maternal vaccines, cancer immunotherapy, and vaccines for highly pathogenic emerging infections, increasing preference for particulate platforms that can support both antibody and cellular immunity. Second, customers are moving away from simple procurement of standard alum and toward adjuvant-system solutions, meaning they increasingly seek not just a raw material but a combined package of formulation know-how, process support, analytics, and licensing. Third, veterinary vaccines remain a stable and meaningful demand base, especially in multivalent products, mucosal immunization, and long-duration protection, where polymeric, gel-based, and hybrid particulate systems retain strong relevance. Overall, the market is unlikely to reward the strongest inflammatory signal alone; instead, future purchasing will favor a balanced combination of breadth of protection, tolerability, dose sparing, elderly immune performance, mucosal potential, and global supply reliability.
LP Information, Inc. (LPI) ' newest research report, the ?Vaccine Particulate Adjuvants Industry Forecast? looks at past sales and reviews total world Vaccine Particulate Adjuvants sales in 2025, providing a comprehensive analysis by region and market sector of projected Vaccine Particulate Adjuvants sales for 2026 through 2032. With Vaccine Particulate Adjuvants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccine Particulate Adjuvants industry.
This Insight Report provides a comprehensive analysis of the global Vaccine Particulate Adjuvants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccine Particulate Adjuvants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Vaccine Particulate Adjuvants market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccine Particulate Adjuvants and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccine Particulate Adjuvants.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine Particulate Adjuvants market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Vaccine Particulate Adjuvants are a class of adjuvants or adjuvant systems that exist as particles, colloids, vesicles, complexes, or other discrete micro- and nanostructures and are used to enhance vaccine immunogenicity, improve antigen delivery, and shape the quality of immune responses. They may appear as milky or translucent suspensions, colloidal dispersions, lyophilized powders, wet gels, or reconstituted particulate systems. Structurally, they commonly consist of inorganic salt particles, lipid bilayer vesicles, saponin-lipid complexes, virosomes, polymeric micro- or nanoparticles, or other biomimetic particulate carriers. Typical components include aluminum hydroxide, aluminum phosphate, cholesterol, phospholipids, saponins, monophosphoryl lipid A analogs, biodegradable polymers, and surface-functional excipients. Their mode of action is not limited to simple immune stimulation; rather, they adsorb, entrap, or co-deliver antigens in a particulate form that is more efficiently taken up by antigen-presenting cells. By tuning particle size, surface charge, rigidity, and interfacial chemistry, they promote cell recruitment at the administration site, lymph node trafficking, dendritic cell activation, and coordinated humoral and cellular immunity. Main categories include aluminum-salt particulates, liposomal adjuvants, virosomal adjuvants, ISCOM/ISCOMATRIX-type adjuvants, polymeric particle adjuvants, and other inorganic or biomimetic particulate adjuvants. Their major applications are in recombinant protein vaccines, subunit vaccines, conjugate vaccines, selected inactivated vaccines, therapeutic cancer vaccines, and veterinary vaccines.
Growth opportunities for Vaccine Particulate Adjuvants are primarily driven by changes in vaccine antigen platforms. Recombinant protein, subunit, conjugate, and many therapeutic vaccines are inherently less immunogenic and therefore more dependent on efficient delivery and immune amplification. Particulate systems are well positioned because they function both as carriers and as immune modulators. Mature aluminum-based systems will continue to provide the bulk of demand, while liposomes, ISCOM/Matrix-M, nano-alum, and polymeric particles are expected to gain share in elderly populations, immunologically weaker populations, and indications requiring stronger Th1 or cellular responses. The real opportunity for suppliers is not merely whether an adjuvant is present, but whether they can build scalable, stable, globally registrable adjuvant platforms compatible with new antigen formats. As RSV, malaria, shingles, broad influenza, therapeutic cancer vaccines, and next-generation veterinary vaccines advance, particulate systems that enable antigen sparing, durable immunity, cold-chain practicality, and differentiated protection profiles should continue to gain commercial importance.
The main restraints in this market are not conceptual novelty but scale-up, raw-material consistency, and regulatory comparability. Particulate adjuvants are highly sensitive to particle-size distribution, surface charge, adsorption capacity, reconstitution behavior, stability windows, and batch-to-batch reproducibility. Once a product moves from laboratory work into commercial manufacturing, the allowable process window narrows sharply. Aluminum salts are mature but offer limited differentiation, whereas liposomal and saponin-complex particles can provide stronger performance but demand tighter control of raw material purity, loading strategy, freeze-thaw stability, analytical methods, and supply-chain security. Critical inputs such as QS-21, MPL-like molecules, specialty lipids, and high-purity phospholipids may also be constrained by plant sourcing, licensing, purification routes, and global production footprint. For investors and industrial analysts, the central risk is to confuse ?works in research? with ?can be manufactured reproducibly at scale,? or to mistake a captive in-house vaccine adjuvant platform for an externally scalable commercial adjuvant business. Competition will therefore increasingly center on CMC, regulatory pathways, intellectual property, and manufacturing scale rather than preclinical efficacy alone.
Downstream demand is showing three clear trends. First, demand is expanding from traditional pediatric immunization into vaccines for older adults, maternal vaccines, cancer immunotherapy, and vaccines for highly pathogenic emerging infections, increasing preference for particulate platforms that can support both antibody and cellular immunity. Second, customers are moving away from simple procurement of standard alum and toward adjuvant-system solutions, meaning they increasingly seek not just a raw material but a combined package of formulation know-how, process support, analytics, and licensing. Third, veterinary vaccines remain a stable and meaningful demand base, especially in multivalent products, mucosal immunization, and long-duration protection, where polymeric, gel-based, and hybrid particulate systems retain strong relevance. Overall, the market is unlikely to reward the strongest inflammatory signal alone; instead, future purchasing will favor a balanced combination of breadth of protection, tolerability, dose sparing, elderly immune performance, mucosal potential, and global supply reliability.
LP Information, Inc. (LPI) ' newest research report, the ?Vaccine Particulate Adjuvants Industry Forecast? looks at past sales and reviews total world Vaccine Particulate Adjuvants sales in 2025, providing a comprehensive analysis by region and market sector of projected Vaccine Particulate Adjuvants sales for 2026 through 2032. With Vaccine Particulate Adjuvants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccine Particulate Adjuvants industry.
This Insight Report provides a comprehensive analysis of the global Vaccine Particulate Adjuvants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccine Particulate Adjuvants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Vaccine Particulate Adjuvants market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccine Particulate Adjuvants and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccine Particulate Adjuvants.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine Particulate Adjuvants market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Oral
- Subcutaneous
- Intranasal
- Intramuscular
- Intradermal
- Others
- Mineral gel / precipitated particles
- Liposomal vesicles
- Virosomal vesicles
- Saponin nanoparticle / ISCOM-type complexes
- Polymeric micro- or nanoparticles
- Others
- Aluminum salt-based particulate adjuvants
- Phospholipid-based particulate adjuvants
- Saponin-based particulate adjuvants
- Polymer-based particulate adjuvants
- Virus-membrane / virosome-based particulate adjuvants
- Hybrid particulate systems
- Others
- Surface-adsorbed particulate systems
- Encapsulated particulate systems
- Co-assembled particulate systems
- Admixture particulate systems
- Others
- Infectious Diseases
- Cancer
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Merck
- Sanofi
- Croda
- Novavax
- SPI Pharma
- CSL
- Serum Institute of India
- Bharat Biotech
- Biological E
- Panacea Biotec
- Valneva
- SEPPIC
- Phibro Animal Health
- Aurorium
- Agenus
- InvivoGen
- OZ Biosciences
- Vaxine
- Adjuvatis
- Desert King
- Sinovac
- China National Biotec Group
- Walvax
- Anhui Zhifei Longcom
- What is the 10-year outlook for the global Vaccine Particulate Adjuvants market?
- What factors are driving Vaccine Particulate Adjuvants market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Vaccine Particulate Adjuvants market opportunities vary by end market size?
- How does Vaccine Particulate Adjuvants break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccine Particulate Adjuvants Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Vaccine Particulate Adjuvants by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Vaccine Particulate Adjuvants by Country/Region, 2021, 2025 & 2032
2.2 Vaccine Particulate Adjuvants Segment by Type
2.2.1 Oral
2.2.2 Subcutaneous
2.2.3 Intranasal
2.2.4 Intramuscular
2.2.5 Intradermal
2.2.6 Others
2.2.7 Vaccine Particulate Adjuvants Sales by Type
2.2.7.1 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
2.2.7.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Vaccine Particulate Adjuvants Sale Price by Type (2021-2026)
2.3 Vaccine Particulate Adjuvants Segment by Particle Architecture
2.3.1 Mineral gel / precipitated particles
2.3.2 Liposomal vesicles
2.3.3 Virosomal vesicles
2.3.4 Saponin nanoparticle / ISCOM-type complexes
2.3.5 Polymeric micro- or nanoparticles
2.3.6 Others
2.3.7 Vaccine Particulate Adjuvants Sales by Particle Architecture
2.3.7.1 Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture (2021-2026)
2.3.7.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Particle Architecture (2021-2026)
2.3.7.3 Global Vaccine Particulate Adjuvants Sale Price by Particle Architecture (2021-2026)
2.4 Vaccine Particulate Adjuvants Segment by Material Composition
2.4.1 Aluminum salt-based particulate adjuvants
2.4.2 Phospholipid-based particulate adjuvants
2.4.3 Saponin-based particulate adjuvants
2.4.4 Polymer-based particulate adjuvants
2.4.5 Virus-membrane / virosome-based particulate adjuvants
2.4.6 Hybrid particulate systems
2.4.7 Others
2.4.8 Vaccine Particulate Adjuvants Sales by Material Composition
2.4.8.1 Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition (2021-2026)
2.4.8.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Material Composition (2021-2026)
2.4.8.3 Global Vaccine Particulate Adjuvants Sale Price by Material Composition (2021-2026)
2.5 Vaccine Particulate Adjuvants Segment by Antigen Association Mode
2.5.1 Surface-adsorbed particulate systems
2.5.2 Encapsulated particulate systems
2.5.3 Co-assembled particulate systems
2.5.4 Admixture particulate systems
2.5.5 Others
2.5.6 Vaccine Particulate Adjuvants Sales by Antigen Association Mode
2.5.6.1 Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode (2021-2026)
2.5.6.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Antigen Association Mode (2021-2026)
2.5.6.3 Global Vaccine Particulate Adjuvants Sale Price by Antigen Association Mode (2021-2026)
2.6 Vaccine Particulate Adjuvants Segment by Application
2.6.1 Infectious Diseases
2.6.2 Cancer
2.6.3 Others
2.6.4 Vaccine Particulate Adjuvants Sales by Application
2.6.4.1 Global Vaccine Particulate Adjuvants Sale Market Share by Application (2021-2026)
2.6.4.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Application (2021-2026)
2.6.4.3 Global Vaccine Particulate Adjuvants Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Vaccine Particulate Adjuvants Breakdown Data by Company
3.1.1 Global Vaccine Particulate Adjuvants Annual Sales by Company (2021-2026)
3.1.2 Global Vaccine Particulate Adjuvants Sales Market Share by Company (2021-2026)
3.2 Global Vaccine Particulate Adjuvants Annual Revenue by Company (2021-2026)
3.2.1 Global Vaccine Particulate Adjuvants Revenue by Company (2021-2026)
3.2.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Company (2021-2026)
3.3 Global Vaccine Particulate Adjuvants Sale Price by Company
3.4 Key Manufacturers Vaccine Particulate Adjuvants Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccine Particulate Adjuvants Product Location Distribution
3.4.2 Players Vaccine Particulate Adjuvants Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VACCINE PARTICULATE ADJUVANTS BY GEOGRAPHIC REGION
4.1 World Historic Vaccine Particulate Adjuvants Market Size by Geographic Region (2021-2026)
4.1.1 Global Vaccine Particulate Adjuvants Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Vaccine Particulate Adjuvants Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Vaccine Particulate Adjuvants Market Size by Country/Region (2021-2026)
4.2.1 Global Vaccine Particulate Adjuvants Annual Sales by Country/Region (2021-2026)
4.2.2 Global Vaccine Particulate Adjuvants Annual Revenue by Country/Region (2021-2026)
4.3 Americas Vaccine Particulate Adjuvants Sales Growth
4.4 APAC Vaccine Particulate Adjuvants Sales Growth
4.5 Europe Vaccine Particulate Adjuvants Sales Growth
4.6 Middle East & Africa Vaccine Particulate Adjuvants Sales Growth
5 AMERICAS
5.1 Americas Vaccine Particulate Adjuvants Sales by Country
5.1.1 Americas Vaccine Particulate Adjuvants Sales by Country (2021-2026)
5.1.2 Americas Vaccine Particulate Adjuvants Revenue by Country (2021-2026)
5.2 Americas Vaccine Particulate Adjuvants Sales by Type (2021-2026)
5.3 Americas Vaccine Particulate Adjuvants Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccine Particulate Adjuvants Sales by Region
6.1.1 APAC Vaccine Particulate Adjuvants Sales by Region (2021-2026)
6.1.2 APAC Vaccine Particulate Adjuvants Revenue by Region (2021-2026)
6.2 APAC Vaccine Particulate Adjuvants Sales by Type (2021-2026)
6.3 APAC Vaccine Particulate Adjuvants Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccine Particulate Adjuvants by Country
7.1.1 Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026)
7.1.2 Europe Vaccine Particulate Adjuvants Revenue by Country (2021-2026)
7.2 Europe Vaccine Particulate Adjuvants Sales by Type (2021-2026)
7.3 Europe Vaccine Particulate Adjuvants Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccine Particulate Adjuvants by Country
8.1.1 Middle East & Africa Vaccine Particulate Adjuvants Sales by Country (2021-2026)
8.1.2 Middle East & Africa Vaccine Particulate Adjuvants Revenue by Country (2021-2026)
8.2 Middle East & Africa Vaccine Particulate Adjuvants Sales by Type (2021-2026)
8.3 Middle East & Africa Vaccine Particulate Adjuvants Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccine Particulate Adjuvants
10.3 Manufacturing Process Analysis of Vaccine Particulate Adjuvants
10.4 Industry Chain Structure of Vaccine Particulate Adjuvants
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccine Particulate Adjuvants Distributors
11.3 Vaccine Particulate Adjuvants Customer
12 WORLD FORECAST REVIEW FOR VACCINE PARTICULATE ADJUVANTS BY GEOGRAPHIC REGION
12.1 Global Vaccine Particulate Adjuvants Market Size Forecast by Region
12.1.1 Global Vaccine Particulate Adjuvants Forecast by Region (2027-2032)
12.1.2 Global Vaccine Particulate Adjuvants Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Vaccine Particulate Adjuvants Forecast by Type (2027-2032)
12.7 Global Vaccine Particulate Adjuvants Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.1.3 GSK Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.2.3 Merck Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.3.3 Sanofi Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Croda
13.4.1 Croda Company Information
13.4.2 Croda Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.4.3 Croda Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Croda Main Business Overview
13.4.5 Croda Latest Developments
13.5 Novavax
13.5.1 Novavax Company Information
13.5.2 Novavax Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.5.3 Novavax Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Novavax Main Business Overview
13.5.5 Novavax Latest Developments
13.6 SPI Pharma
13.6.1 SPI Pharma Company Information
13.6.2 SPI Pharma Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.6.3 SPI Pharma Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 SPI Pharma Main Business Overview
13.6.5 SPI Pharma Latest Developments
13.7 CSL
13.7.1 CSL Company Information
13.7.2 CSL Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.7.3 CSL Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 CSL Main Business Overview
13.7.5 CSL Latest Developments
13.8 Serum Institute of India
13.8.1 Serum Institute of India Company Information
13.8.2 Serum Institute of India Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.8.3 Serum Institute of India Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Serum Institute of India Main Business Overview
13.8.5 Serum Institute of India Latest Developments
13.9 Bharat Biotech
13.9.1 Bharat Biotech Company Information
13.9.2 Bharat Biotech Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.9.3 Bharat Biotech Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Bharat Biotech Main Business Overview
13.9.5 Bharat Biotech Latest Developments
13.10 Biological E
13.10.1 Biological E Company Information
13.10.2 Biological E Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.10.3 Biological E Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Biological E Main Business Overview
13.10.5 Biological E Latest Developments
13.11 Panacea Biotec
13.11.1 Panacea Biotec Company Information
13.11.2 Panacea Biotec Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.11.3 Panacea Biotec Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Panacea Biotec Main Business Overview
13.11.5 Panacea Biotec Latest Developments
13.12 Valneva
13.12.1 Valneva Company Information
13.12.2 Valneva Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.12.3 Valneva Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Valneva Main Business Overview
13.12.5 Valneva Latest Developments
13.13 SEPPIC
13.13.1 SEPPIC Company Information
13.13.2 SEPPIC Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.13.3 SEPPIC Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 SEPPIC Main Business Overview
13.13.5 SEPPIC Latest Developments
13.14 Phibro Animal Health
13.14.1 Phibro Animal Health Company Information
13.14.2 Phibro Animal Health Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.14.3 Phibro Animal Health Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Phibro Animal Health Main Business Overview
13.14.5 Phibro Animal Health Latest Developments
13.15 Aurorium
13.15.1 Aurorium Company Information
13.15.2 Aurorium Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.15.3 Aurorium Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Aurorium Main Business Overview
13.15.5 Aurorium Latest Developments
13.16 Agenus
13.16.1 Agenus Company Information
13.16.2 Agenus Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.16.3 Agenus Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Agenus Main Business Overview
13.16.5 Agenus Latest Developments
13.17 InvivoGen
13.17.1 InvivoGen Company Information
13.17.2 InvivoGen Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.17.3 InvivoGen Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 InvivoGen Main Business Overview
13.17.5 InvivoGen Latest Developments
13.18 OZ Biosciences
13.18.1 OZ Biosciences Company Information
13.18.2 OZ Biosciences Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.18.3 OZ Biosciences Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 OZ Biosciences Main Business Overview
13.18.5 OZ Biosciences Latest Developments
13.19 Vaxine
13.19.1 Vaxine Company Information
13.19.2 Vaxine Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.19.3 Vaxine Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Vaxine Main Business Overview
13.19.5 Vaxine Latest Developments
13.20 Adjuvatis
13.20.1 Adjuvatis Company Information
13.20.2 Adjuvatis Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.20.3 Adjuvatis Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Adjuvatis Main Business Overview
13.20.5 Adjuvatis Latest Developments
13.21 Desert King
13.21.1 Desert King Company Information
13.21.2 Desert King Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.21.3 Desert King Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Desert King Main Business Overview
13.21.5 Desert King Latest Developments
13.22 Sinovac
13.22.1 Sinovac Company Information
13.22.2 Sinovac Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.22.3 Sinovac Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Sinovac Main Business Overview
13.22.5 Sinovac Latest Developments
13.23 China National Biotec Group
13.23.1 China National Biotec Group Company Information
13.23.2 China National Biotec Group Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.23.3 China National Biotec Group Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 China National Biotec Group Main Business Overview
13.23.5 China National Biotec Group Latest Developments
13.24 Walvax
13.24.1 Walvax Company Information
13.24.2 Walvax Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.24.3 Walvax Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Walvax Main Business Overview
13.24.5 Walvax Latest Developments
13.25 Anhui Zhifei Longcom
13.25.1 Anhui Zhifei Longcom Company Information
13.25.2 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.25.3 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Anhui Zhifei Longcom Main Business Overview
13.25.5 Anhui Zhifei Longcom Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccine Particulate Adjuvants Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Vaccine Particulate Adjuvants by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Vaccine Particulate Adjuvants by Country/Region, 2021, 2025 & 2032
2.2 Vaccine Particulate Adjuvants Segment by Type
2.2.1 Oral
2.2.2 Subcutaneous
2.2.3 Intranasal
2.2.4 Intramuscular
2.2.5 Intradermal
2.2.6 Others
2.2.7 Vaccine Particulate Adjuvants Sales by Type
2.2.7.1 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
2.2.7.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Vaccine Particulate Adjuvants Sale Price by Type (2021-2026)
2.3 Vaccine Particulate Adjuvants Segment by Particle Architecture
2.3.1 Mineral gel / precipitated particles
2.3.2 Liposomal vesicles
2.3.3 Virosomal vesicles
2.3.4 Saponin nanoparticle / ISCOM-type complexes
2.3.5 Polymeric micro- or nanoparticles
2.3.6 Others
2.3.7 Vaccine Particulate Adjuvants Sales by Particle Architecture
2.3.7.1 Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture (2021-2026)
2.3.7.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Particle Architecture (2021-2026)
2.3.7.3 Global Vaccine Particulate Adjuvants Sale Price by Particle Architecture (2021-2026)
2.4 Vaccine Particulate Adjuvants Segment by Material Composition
2.4.1 Aluminum salt-based particulate adjuvants
2.4.2 Phospholipid-based particulate adjuvants
2.4.3 Saponin-based particulate adjuvants
2.4.4 Polymer-based particulate adjuvants
2.4.5 Virus-membrane / virosome-based particulate adjuvants
2.4.6 Hybrid particulate systems
2.4.7 Others
2.4.8 Vaccine Particulate Adjuvants Sales by Material Composition
2.4.8.1 Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition (2021-2026)
2.4.8.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Material Composition (2021-2026)
2.4.8.3 Global Vaccine Particulate Adjuvants Sale Price by Material Composition (2021-2026)
2.5 Vaccine Particulate Adjuvants Segment by Antigen Association Mode
2.5.1 Surface-adsorbed particulate systems
2.5.2 Encapsulated particulate systems
2.5.3 Co-assembled particulate systems
2.5.4 Admixture particulate systems
2.5.5 Others
2.5.6 Vaccine Particulate Adjuvants Sales by Antigen Association Mode
2.5.6.1 Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode (2021-2026)
2.5.6.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Antigen Association Mode (2021-2026)
2.5.6.3 Global Vaccine Particulate Adjuvants Sale Price by Antigen Association Mode (2021-2026)
2.6 Vaccine Particulate Adjuvants Segment by Application
2.6.1 Infectious Diseases
2.6.2 Cancer
2.6.3 Others
2.6.4 Vaccine Particulate Adjuvants Sales by Application
2.6.4.1 Global Vaccine Particulate Adjuvants Sale Market Share by Application (2021-2026)
2.6.4.2 Global Vaccine Particulate Adjuvants Revenue and Market Share by Application (2021-2026)
2.6.4.3 Global Vaccine Particulate Adjuvants Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Vaccine Particulate Adjuvants Breakdown Data by Company
3.1.1 Global Vaccine Particulate Adjuvants Annual Sales by Company (2021-2026)
3.1.2 Global Vaccine Particulate Adjuvants Sales Market Share by Company (2021-2026)
3.2 Global Vaccine Particulate Adjuvants Annual Revenue by Company (2021-2026)
3.2.1 Global Vaccine Particulate Adjuvants Revenue by Company (2021-2026)
3.2.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Company (2021-2026)
3.3 Global Vaccine Particulate Adjuvants Sale Price by Company
3.4 Key Manufacturers Vaccine Particulate Adjuvants Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccine Particulate Adjuvants Product Location Distribution
3.4.2 Players Vaccine Particulate Adjuvants Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VACCINE PARTICULATE ADJUVANTS BY GEOGRAPHIC REGION
4.1 World Historic Vaccine Particulate Adjuvants Market Size by Geographic Region (2021-2026)
4.1.1 Global Vaccine Particulate Adjuvants Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Vaccine Particulate Adjuvants Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Vaccine Particulate Adjuvants Market Size by Country/Region (2021-2026)
4.2.1 Global Vaccine Particulate Adjuvants Annual Sales by Country/Region (2021-2026)
4.2.2 Global Vaccine Particulate Adjuvants Annual Revenue by Country/Region (2021-2026)
4.3 Americas Vaccine Particulate Adjuvants Sales Growth
4.4 APAC Vaccine Particulate Adjuvants Sales Growth
4.5 Europe Vaccine Particulate Adjuvants Sales Growth
4.6 Middle East & Africa Vaccine Particulate Adjuvants Sales Growth
5 AMERICAS
5.1 Americas Vaccine Particulate Adjuvants Sales by Country
5.1.1 Americas Vaccine Particulate Adjuvants Sales by Country (2021-2026)
5.1.2 Americas Vaccine Particulate Adjuvants Revenue by Country (2021-2026)
5.2 Americas Vaccine Particulate Adjuvants Sales by Type (2021-2026)
5.3 Americas Vaccine Particulate Adjuvants Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccine Particulate Adjuvants Sales by Region
6.1.1 APAC Vaccine Particulate Adjuvants Sales by Region (2021-2026)
6.1.2 APAC Vaccine Particulate Adjuvants Revenue by Region (2021-2026)
6.2 APAC Vaccine Particulate Adjuvants Sales by Type (2021-2026)
6.3 APAC Vaccine Particulate Adjuvants Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccine Particulate Adjuvants by Country
7.1.1 Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026)
7.1.2 Europe Vaccine Particulate Adjuvants Revenue by Country (2021-2026)
7.2 Europe Vaccine Particulate Adjuvants Sales by Type (2021-2026)
7.3 Europe Vaccine Particulate Adjuvants Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccine Particulate Adjuvants by Country
8.1.1 Middle East & Africa Vaccine Particulate Adjuvants Sales by Country (2021-2026)
8.1.2 Middle East & Africa Vaccine Particulate Adjuvants Revenue by Country (2021-2026)
8.2 Middle East & Africa Vaccine Particulate Adjuvants Sales by Type (2021-2026)
8.3 Middle East & Africa Vaccine Particulate Adjuvants Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccine Particulate Adjuvants
10.3 Manufacturing Process Analysis of Vaccine Particulate Adjuvants
10.4 Industry Chain Structure of Vaccine Particulate Adjuvants
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccine Particulate Adjuvants Distributors
11.3 Vaccine Particulate Adjuvants Customer
12 WORLD FORECAST REVIEW FOR VACCINE PARTICULATE ADJUVANTS BY GEOGRAPHIC REGION
12.1 Global Vaccine Particulate Adjuvants Market Size Forecast by Region
12.1.1 Global Vaccine Particulate Adjuvants Forecast by Region (2027-2032)
12.1.2 Global Vaccine Particulate Adjuvants Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Vaccine Particulate Adjuvants Forecast by Type (2027-2032)
12.7 Global Vaccine Particulate Adjuvants Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.1.3 GSK Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.2.3 Merck Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.3.3 Sanofi Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Croda
13.4.1 Croda Company Information
13.4.2 Croda Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.4.3 Croda Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Croda Main Business Overview
13.4.5 Croda Latest Developments
13.5 Novavax
13.5.1 Novavax Company Information
13.5.2 Novavax Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.5.3 Novavax Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Novavax Main Business Overview
13.5.5 Novavax Latest Developments
13.6 SPI Pharma
13.6.1 SPI Pharma Company Information
13.6.2 SPI Pharma Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.6.3 SPI Pharma Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 SPI Pharma Main Business Overview
13.6.5 SPI Pharma Latest Developments
13.7 CSL
13.7.1 CSL Company Information
13.7.2 CSL Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.7.3 CSL Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 CSL Main Business Overview
13.7.5 CSL Latest Developments
13.8 Serum Institute of India
13.8.1 Serum Institute of India Company Information
13.8.2 Serum Institute of India Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.8.3 Serum Institute of India Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Serum Institute of India Main Business Overview
13.8.5 Serum Institute of India Latest Developments
13.9 Bharat Biotech
13.9.1 Bharat Biotech Company Information
13.9.2 Bharat Biotech Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.9.3 Bharat Biotech Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Bharat Biotech Main Business Overview
13.9.5 Bharat Biotech Latest Developments
13.10 Biological E
13.10.1 Biological E Company Information
13.10.2 Biological E Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.10.3 Biological E Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Biological E Main Business Overview
13.10.5 Biological E Latest Developments
13.11 Panacea Biotec
13.11.1 Panacea Biotec Company Information
13.11.2 Panacea Biotec Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.11.3 Panacea Biotec Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Panacea Biotec Main Business Overview
13.11.5 Panacea Biotec Latest Developments
13.12 Valneva
13.12.1 Valneva Company Information
13.12.2 Valneva Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.12.3 Valneva Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Valneva Main Business Overview
13.12.5 Valneva Latest Developments
13.13 SEPPIC
13.13.1 SEPPIC Company Information
13.13.2 SEPPIC Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.13.3 SEPPIC Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 SEPPIC Main Business Overview
13.13.5 SEPPIC Latest Developments
13.14 Phibro Animal Health
13.14.1 Phibro Animal Health Company Information
13.14.2 Phibro Animal Health Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.14.3 Phibro Animal Health Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Phibro Animal Health Main Business Overview
13.14.5 Phibro Animal Health Latest Developments
13.15 Aurorium
13.15.1 Aurorium Company Information
13.15.2 Aurorium Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.15.3 Aurorium Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Aurorium Main Business Overview
13.15.5 Aurorium Latest Developments
13.16 Agenus
13.16.1 Agenus Company Information
13.16.2 Agenus Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.16.3 Agenus Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Agenus Main Business Overview
13.16.5 Agenus Latest Developments
13.17 InvivoGen
13.17.1 InvivoGen Company Information
13.17.2 InvivoGen Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.17.3 InvivoGen Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 InvivoGen Main Business Overview
13.17.5 InvivoGen Latest Developments
13.18 OZ Biosciences
13.18.1 OZ Biosciences Company Information
13.18.2 OZ Biosciences Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.18.3 OZ Biosciences Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 OZ Biosciences Main Business Overview
13.18.5 OZ Biosciences Latest Developments
13.19 Vaxine
13.19.1 Vaxine Company Information
13.19.2 Vaxine Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.19.3 Vaxine Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Vaxine Main Business Overview
13.19.5 Vaxine Latest Developments
13.20 Adjuvatis
13.20.1 Adjuvatis Company Information
13.20.2 Adjuvatis Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.20.3 Adjuvatis Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Adjuvatis Main Business Overview
13.20.5 Adjuvatis Latest Developments
13.21 Desert King
13.21.1 Desert King Company Information
13.21.2 Desert King Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.21.3 Desert King Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Desert King Main Business Overview
13.21.5 Desert King Latest Developments
13.22 Sinovac
13.22.1 Sinovac Company Information
13.22.2 Sinovac Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.22.3 Sinovac Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Sinovac Main Business Overview
13.22.5 Sinovac Latest Developments
13.23 China National Biotec Group
13.23.1 China National Biotec Group Company Information
13.23.2 China National Biotec Group Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.23.3 China National Biotec Group Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 China National Biotec Group Main Business Overview
13.23.5 China National Biotec Group Latest Developments
13.24 Walvax
13.24.1 Walvax Company Information
13.24.2 Walvax Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.24.3 Walvax Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Walvax Main Business Overview
13.24.5 Walvax Latest Developments
13.25 Anhui Zhifei Longcom
13.25.1 Anhui Zhifei Longcom Company Information
13.25.2 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product Portfolios and Specifications
13.25.3 Anhui Zhifei Longcom Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Anhui Zhifei Longcom Main Business Overview
13.25.5 Anhui Zhifei Longcom Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Vaccine Particulate Adjuvants Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Vaccine Particulate Adjuvants Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Subcutaneous
Table 5. Major Players of Intranasal
Table 6. Major Players of Intramuscular
Table 7. Major Players of Intradermal
Table 8. Major Players of Others
Table 9. Global Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 10. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Table 11. Global Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & ($ million)
Table 12. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026)
Table 13. Global Vaccine Particulate Adjuvants Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Major Players of Mineral gel / precipitated particles
Table 15. Major Players of Liposomal vesicles
Table 16. Major Players of Virosomal vesicles
Table 17. Major Players of Saponin nanoparticle / ISCOM-type complexes
Table 18. Major Players of Polymeric micro- or nanoparticles
Table 19. Major Players of Others
Table 20. Global Vaccine Particulate Adjuvants Sales by Particle Architecture (2021-2026) & (K Units)
Table 21. Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture (2021-2026)
Table 22. Global Vaccine Particulate Adjuvants Revenue by Particle Architecture (2021-2026) & ($ million)
Table 23. Global Vaccine Particulate Adjuvants Revenue Market Share by Particle Architecture (2021-2026)
Table 24. Global Vaccine Particulate Adjuvants Sale Price by Particle Architecture (2021-2026) & (US$/Unit)
Table 25. Major Players of Aluminum salt-based particulate adjuvants
Table 26. Major Players of Phospholipid-based particulate adjuvants
Table 27. Major Players of Saponin-based particulate adjuvants
Table 28. Major Players of Polymer-based particulate adjuvants
Table 29. Major Players of Virus-membrane / virosome-based particulate adjuvants
Table 30. Major Players of Hybrid particulate systems
Table 31. Major Players of Others
Table 32. Global Vaccine Particulate Adjuvants Sales by Material Composition (2021-2026) & (K Units)
Table 33. Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition (2021-2026)
Table 34. Global Vaccine Particulate Adjuvants Revenue by Material Composition (2021-2026) & ($ million)
Table 35. Global Vaccine Particulate Adjuvants Revenue Market Share by Material Composition (2021-2026)
Table 36. Global Vaccine Particulate Adjuvants Sale Price by Material Composition (2021-2026) & (US$/Unit)
Table 37. Major Players of Surface-adsorbed particulate systems
Table 38. Major Players of Encapsulated particulate systems
Table 39. Major Players of Co-assembled particulate systems
Table 40. Major Players of Admixture particulate systems
Table 41. Major Players of Others
Table 42. Global Vaccine Particulate Adjuvants Sales by Antigen Association Mode (2021-2026) & (K Units)
Table 43. Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode (2021-2026)
Table 44. Global Vaccine Particulate Adjuvants Revenue by Antigen Association Mode (2021-2026) & ($ million)
Table 45. Global Vaccine Particulate Adjuvants Revenue Market Share by Antigen Association Mode (2021-2026)
Table 46. Global Vaccine Particulate Adjuvants Sale Price by Antigen Association Mode (2021-2026) & (US$/Unit)
Table 47. Global Vaccine Particulate Adjuvants Sale by Application (2021-2026) & (K Units)
Table 48. Global Vaccine Particulate Adjuvants Sale Market Share by Application (2021-2026)
Table 49. Global Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & ($ million)
Table 50. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2026)
Table 51. Global Vaccine Particulate Adjuvants Sale Price by Application (2021-2026) & (US$/Unit)
Table 52. Global Vaccine Particulate Adjuvants Sales by Company (2021-2026) & (K Units)
Table 53. Global Vaccine Particulate Adjuvants Sales Market Share by Company (2021-2026)
Table 54. Global Vaccine Particulate Adjuvants Revenue by Company (2021-2026) & ($ millions)
Table 55. Global Vaccine Particulate Adjuvants Revenue Market Share by Company (2021-2026)
Table 56. Global Vaccine Particulate Adjuvants Sale Price by Company (2021-2026) & (US$/Unit)
Table 57. Key Manufacturers Vaccine Particulate Adjuvants Producing Area Distribution and Sales Area
Table 58. Players Vaccine Particulate Adjuvants Products Offered
Table 59. Vaccine Particulate Adjuvants Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 60. New Products and Potential Entrants
Table 61. Market M&A Activity & Strategy
Table 62. Global Vaccine Particulate Adjuvants Sales by Geographic Region (2021-2026) & (K Units)
Table 63. Global Vaccine Particulate Adjuvants Sales Market Share Geographic Region (2021-2026)
Table 64. Global Vaccine Particulate Adjuvants Revenue by Geographic Region (2021-2026) & ($ millions)
Table 65. Global Vaccine Particulate Adjuvants Revenue Market Share by Geographic Region (2021-2026)
Table 66. Global Vaccine Particulate Adjuvants Sales by Country/Region (2021-2026) & (K Units)
Table 67. Global Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2021-2026)
Table 68. Global Vaccine Particulate Adjuvants Revenue by Country/Region (2021-2026) & ($ millions)
Table 69. Global Vaccine Particulate Adjuvants Revenue Market Share by Country/Region (2021-2026)
Table 70. Americas Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)
Table 71. Americas Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2026)
Table 72. Americas Vaccine Particulate Adjuvants Revenue by Country (2021-2026) & ($ millions)
Table 73. Americas Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 74. Americas Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 75. APAC Vaccine Particulate Adjuvants Sales by Region (2021-2026) & (K Units)
Table 76. APAC Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2026)
Table 77. APAC Vaccine Particulate Adjuvants Revenue by Region (2021-2026) & ($ millions)
Table 78. APAC Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 79. APAC Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 80. Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)
Table 81. Europe Vaccine Particulate Adjuvants Revenue by Country (2021-2026) & ($ millions)
Table 82. Europe Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 83. Europe Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 84. Middle East & Africa Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)
Table 85. Middle East & Africa Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)
Table 86. Middle East & Africa Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 87. Middle East & Africa Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 88. Key Market Drivers & Growth Opportunities of Vaccine Particulate Adjuvants
Table 89. Key Market Challenges & Risks of Vaccine Particulate Adjuvants
Table 90. Key Industry Trends of Vaccine Particulate Adjuvants
Table 91. Vaccine Particulate Adjuvants Raw Material
Table 92. Key Suppliers of Raw Materials
Table 93. Vaccine Particulate Adjuvants Distributors List
Table 94. Vaccine Particulate Adjuvants Customer List
Table 95. Global Vaccine Particulate Adjuvants Sales Forecast by Region (2027-2032) & (K Units)
Table 96. Global Vaccine Particulate Adjuvants Revenue Forecast by Region (2027-2032) & ($ millions)
Table 97. Americas Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)
Table 98. Americas Vaccine Particulate Adjuvants Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 99. APAC Vaccine Particulate Adjuvants Sales Forecast by Region (2027-2032) & (K Units)
Table 100. APAC Vaccine Particulate Adjuvants Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 101. Europe Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)
Table 102. Europe Vaccine Particulate Adjuvants Revenue Forecast by Country (2027-2032) & ($ millions)
Table 103. Middle East & Africa Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)
Table 104. Middle East & Africa Vaccine Particulate Adjuvants Revenue Forecast by Country (2027-2032) & ($ millions)
Table 105. Global Vaccine Particulate Adjuvants Sales Forecast by Type (2027-2032) & (K Units)
Table 106. Global Vaccine Particulate Adjuvants Revenue Forecast by Type (2027-2032) & ($ millions)
Table 107. Global Vaccine Particulate Adjuvants Sales Forecast by Application (2027-2032) & (K Units)
Table 108. Global Vaccine Particulate Adjuvants Revenue Forecast by Application (2027-2032) & ($ millions)
Table 109. GSK Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 110. GSK Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 111. GSK Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. GSK Main Business
Table 113. GSK Latest Developments
Table 114. Merck Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 115. Merck Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 116. Merck Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Merck Main Business
Table 118. Merck Latest Developments
Table 119. Sanofi Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 120. Sanofi Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 121. Sanofi Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Sanofi Main Business
Table 123. Sanofi Latest Developments
Table 124. Croda Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 125. Croda Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 126. Croda Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Croda Main Business
Table 128. Croda Latest Developments
Table 129. Novavax Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 130. Novavax Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 131. Novavax Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Novavax Main Business
Table 133. Novavax Latest Developments
Table 134. SPI Pharma Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 135. SPI Pharma Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 136. SPI Pharma Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. SPI Pharma Main Business
Table 138. SPI Pharma Latest Developments
Table 139. CSL Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 140. CSL Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 141. CSL Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. CSL Main Business
Table 143. CSL Latest Developments
Table 144. Serum Institute of India Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 145. Serum Institute of India Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 146. Serum Institute of India Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Serum Institute of India Main Business
Table 148. Serum Institute of India Latest Developments
Table 149. Bharat Biotech Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 150. Bharat Biotech Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 151. Bharat Biotech Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Bharat Biotech Main Business
Table 153. Bharat Biotech Latest Developments
Table 154. Biological E Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 155. Biological E Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 156. Biological E Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Biological E Main Business
Table 158. Biological E Latest Developments
Table 159. Panacea Biotec Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 160. Panacea Biotec Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 161. Panacea Biotec Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Panacea Biotec Main Business
Table 163. Panacea Biotec Latest Developments
Table 164. Valneva Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 165. Valneva Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 166. Valneva Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Valneva Main Business
Table 168. Valneva Latest Developments
Table 169. SEPPIC Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 170. SEPPIC Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 171. SEPPIC Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. SEPPIC Main Business
Table 173. SEPPIC Latest Developments
Table 174. Phibro Animal Health Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 175. Phibro Animal Health Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 176. Phibro Animal Health Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Phibro Animal Health Main Business
Table 178. Phibro Animal Health Latest Developments
Table 179. Aurorium Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 180. Aurorium Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 181. Aurorium Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. Aurorium Main Business
Table 183. Aurorium Latest Developments
Table 184. Agenus Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 185. Agenus Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 186. Agenus Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Agenus Main Business
Table 188. Agenus Latest Developments
Table 189. InvivoGen Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 190. InvivoGen Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 191. InvivoGen Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 192. InvivoGen Main Business
Table 193. InvivoGen Latest Developments
Table 194. OZ Biosciences Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 195. OZ Biosciences Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 196. OZ Biosciences Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 197. OZ Biosciences Main Business
Table 198. OZ Biosciences Latest Developments
Table 199. Vaxine Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 200. Vaxine Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 201. Vaxine Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 202. Vaxine Main Business
Table 203. Vaxine Latest Developments
Table 204. Adjuvatis Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 205. Adjuvatis Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 206. Adjuvatis Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 207. Adjuvatis Main Business
Table 208. Adjuvatis Latest Developments
Table 209. Desert King Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 210. Desert King Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 211. Desert King Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 212. Desert King Main Business
Table 213. Desert King Latest Developments
Table 214. Sinovac Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 215. Sinovac Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 216. Sinovac Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 217. Sinovac Main Business
Table 218. Sinovac Latest Developments
Table 219. China National Biotec Group Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 220. China National Biotec Group Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 221. China National Biotec Group Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 222. China National Biotec Group Main Business
Table 223. China National Biotec Group Latest Developments
Table 224. Walvax Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 225. Walvax Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 226. Walvax Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 227. Walvax Main Business
Table 228. Walvax Latest Developments
Table 229. Anhui Zhifei Longcom Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 230. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 231. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 232. Anhui Zhifei Longcom Main Business
Table 233. Anhui Zhifei Longcom Latest Developments
Table 1. Vaccine Particulate Adjuvants Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Vaccine Particulate Adjuvants Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Subcutaneous
Table 5. Major Players of Intranasal
Table 6. Major Players of Intramuscular
Table 7. Major Players of Intradermal
Table 8. Major Players of Others
Table 9. Global Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 10. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Table 11. Global Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & ($ million)
Table 12. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026)
Table 13. Global Vaccine Particulate Adjuvants Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Major Players of Mineral gel / precipitated particles
Table 15. Major Players of Liposomal vesicles
Table 16. Major Players of Virosomal vesicles
Table 17. Major Players of Saponin nanoparticle / ISCOM-type complexes
Table 18. Major Players of Polymeric micro- or nanoparticles
Table 19. Major Players of Others
Table 20. Global Vaccine Particulate Adjuvants Sales by Particle Architecture (2021-2026) & (K Units)
Table 21. Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture (2021-2026)
Table 22. Global Vaccine Particulate Adjuvants Revenue by Particle Architecture (2021-2026) & ($ million)
Table 23. Global Vaccine Particulate Adjuvants Revenue Market Share by Particle Architecture (2021-2026)
Table 24. Global Vaccine Particulate Adjuvants Sale Price by Particle Architecture (2021-2026) & (US$/Unit)
Table 25. Major Players of Aluminum salt-based particulate adjuvants
Table 26. Major Players of Phospholipid-based particulate adjuvants
Table 27. Major Players of Saponin-based particulate adjuvants
Table 28. Major Players of Polymer-based particulate adjuvants
Table 29. Major Players of Virus-membrane / virosome-based particulate adjuvants
Table 30. Major Players of Hybrid particulate systems
Table 31. Major Players of Others
Table 32. Global Vaccine Particulate Adjuvants Sales by Material Composition (2021-2026) & (K Units)
Table 33. Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition (2021-2026)
Table 34. Global Vaccine Particulate Adjuvants Revenue by Material Composition (2021-2026) & ($ million)
Table 35. Global Vaccine Particulate Adjuvants Revenue Market Share by Material Composition (2021-2026)
Table 36. Global Vaccine Particulate Adjuvants Sale Price by Material Composition (2021-2026) & (US$/Unit)
Table 37. Major Players of Surface-adsorbed particulate systems
Table 38. Major Players of Encapsulated particulate systems
Table 39. Major Players of Co-assembled particulate systems
Table 40. Major Players of Admixture particulate systems
Table 41. Major Players of Others
Table 42. Global Vaccine Particulate Adjuvants Sales by Antigen Association Mode (2021-2026) & (K Units)
Table 43. Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode (2021-2026)
Table 44. Global Vaccine Particulate Adjuvants Revenue by Antigen Association Mode (2021-2026) & ($ million)
Table 45. Global Vaccine Particulate Adjuvants Revenue Market Share by Antigen Association Mode (2021-2026)
Table 46. Global Vaccine Particulate Adjuvants Sale Price by Antigen Association Mode (2021-2026) & (US$/Unit)
Table 47. Global Vaccine Particulate Adjuvants Sale by Application (2021-2026) & (K Units)
Table 48. Global Vaccine Particulate Adjuvants Sale Market Share by Application (2021-2026)
Table 49. Global Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & ($ million)
Table 50. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2026)
Table 51. Global Vaccine Particulate Adjuvants Sale Price by Application (2021-2026) & (US$/Unit)
Table 52. Global Vaccine Particulate Adjuvants Sales by Company (2021-2026) & (K Units)
Table 53. Global Vaccine Particulate Adjuvants Sales Market Share by Company (2021-2026)
Table 54. Global Vaccine Particulate Adjuvants Revenue by Company (2021-2026) & ($ millions)
Table 55. Global Vaccine Particulate Adjuvants Revenue Market Share by Company (2021-2026)
Table 56. Global Vaccine Particulate Adjuvants Sale Price by Company (2021-2026) & (US$/Unit)
Table 57. Key Manufacturers Vaccine Particulate Adjuvants Producing Area Distribution and Sales Area
Table 58. Players Vaccine Particulate Adjuvants Products Offered
Table 59. Vaccine Particulate Adjuvants Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 60. New Products and Potential Entrants
Table 61. Market M&A Activity & Strategy
Table 62. Global Vaccine Particulate Adjuvants Sales by Geographic Region (2021-2026) & (K Units)
Table 63. Global Vaccine Particulate Adjuvants Sales Market Share Geographic Region (2021-2026)
Table 64. Global Vaccine Particulate Adjuvants Revenue by Geographic Region (2021-2026) & ($ millions)
Table 65. Global Vaccine Particulate Adjuvants Revenue Market Share by Geographic Region (2021-2026)
Table 66. Global Vaccine Particulate Adjuvants Sales by Country/Region (2021-2026) & (K Units)
Table 67. Global Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2021-2026)
Table 68. Global Vaccine Particulate Adjuvants Revenue by Country/Region (2021-2026) & ($ millions)
Table 69. Global Vaccine Particulate Adjuvants Revenue Market Share by Country/Region (2021-2026)
Table 70. Americas Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)
Table 71. Americas Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2026)
Table 72. Americas Vaccine Particulate Adjuvants Revenue by Country (2021-2026) & ($ millions)
Table 73. Americas Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 74. Americas Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 75. APAC Vaccine Particulate Adjuvants Sales by Region (2021-2026) & (K Units)
Table 76. APAC Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2026)
Table 77. APAC Vaccine Particulate Adjuvants Revenue by Region (2021-2026) & ($ millions)
Table 78. APAC Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 79. APAC Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 80. Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)
Table 81. Europe Vaccine Particulate Adjuvants Revenue by Country (2021-2026) & ($ millions)
Table 82. Europe Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 83. Europe Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 84. Middle East & Africa Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (K Units)
Table 85. Middle East & Africa Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)
Table 86. Middle East & Africa Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (K Units)
Table 87. Middle East & Africa Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (K Units)
Table 88. Key Market Drivers & Growth Opportunities of Vaccine Particulate Adjuvants
Table 89. Key Market Challenges & Risks of Vaccine Particulate Adjuvants
Table 90. Key Industry Trends of Vaccine Particulate Adjuvants
Table 91. Vaccine Particulate Adjuvants Raw Material
Table 92. Key Suppliers of Raw Materials
Table 93. Vaccine Particulate Adjuvants Distributors List
Table 94. Vaccine Particulate Adjuvants Customer List
Table 95. Global Vaccine Particulate Adjuvants Sales Forecast by Region (2027-2032) & (K Units)
Table 96. Global Vaccine Particulate Adjuvants Revenue Forecast by Region (2027-2032) & ($ millions)
Table 97. Americas Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)
Table 98. Americas Vaccine Particulate Adjuvants Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 99. APAC Vaccine Particulate Adjuvants Sales Forecast by Region (2027-2032) & (K Units)
Table 100. APAC Vaccine Particulate Adjuvants Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 101. Europe Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)
Table 102. Europe Vaccine Particulate Adjuvants Revenue Forecast by Country (2027-2032) & ($ millions)
Table 103. Middle East & Africa Vaccine Particulate Adjuvants Sales Forecast by Country (2027-2032) & (K Units)
Table 104. Middle East & Africa Vaccine Particulate Adjuvants Revenue Forecast by Country (2027-2032) & ($ millions)
Table 105. Global Vaccine Particulate Adjuvants Sales Forecast by Type (2027-2032) & (K Units)
Table 106. Global Vaccine Particulate Adjuvants Revenue Forecast by Type (2027-2032) & ($ millions)
Table 107. Global Vaccine Particulate Adjuvants Sales Forecast by Application (2027-2032) & (K Units)
Table 108. Global Vaccine Particulate Adjuvants Revenue Forecast by Application (2027-2032) & ($ millions)
Table 109. GSK Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 110. GSK Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 111. GSK Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. GSK Main Business
Table 113. GSK Latest Developments
Table 114. Merck Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 115. Merck Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 116. Merck Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Merck Main Business
Table 118. Merck Latest Developments
Table 119. Sanofi Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 120. Sanofi Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 121. Sanofi Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Sanofi Main Business
Table 123. Sanofi Latest Developments
Table 124. Croda Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 125. Croda Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 126. Croda Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Croda Main Business
Table 128. Croda Latest Developments
Table 129. Novavax Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 130. Novavax Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 131. Novavax Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Novavax Main Business
Table 133. Novavax Latest Developments
Table 134. SPI Pharma Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 135. SPI Pharma Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 136. SPI Pharma Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. SPI Pharma Main Business
Table 138. SPI Pharma Latest Developments
Table 139. CSL Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 140. CSL Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 141. CSL Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. CSL Main Business
Table 143. CSL Latest Developments
Table 144. Serum Institute of India Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 145. Serum Institute of India Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 146. Serum Institute of India Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Serum Institute of India Main Business
Table 148. Serum Institute of India Latest Developments
Table 149. Bharat Biotech Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 150. Bharat Biotech Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 151. Bharat Biotech Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Bharat Biotech Main Business
Table 153. Bharat Biotech Latest Developments
Table 154. Biological E Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 155. Biological E Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 156. Biological E Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Biological E Main Business
Table 158. Biological E Latest Developments
Table 159. Panacea Biotec Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 160. Panacea Biotec Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 161. Panacea Biotec Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. Panacea Biotec Main Business
Table 163. Panacea Biotec Latest Developments
Table 164. Valneva Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 165. Valneva Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 166. Valneva Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Valneva Main Business
Table 168. Valneva Latest Developments
Table 169. SEPPIC Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 170. SEPPIC Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 171. SEPPIC Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. SEPPIC Main Business
Table 173. SEPPIC Latest Developments
Table 174. Phibro Animal Health Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 175. Phibro Animal Health Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 176. Phibro Animal Health Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Phibro Animal Health Main Business
Table 178. Phibro Animal Health Latest Developments
Table 179. Aurorium Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 180. Aurorium Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 181. Aurorium Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. Aurorium Main Business
Table 183. Aurorium Latest Developments
Table 184. Agenus Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 185. Agenus Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 186. Agenus Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Agenus Main Business
Table 188. Agenus Latest Developments
Table 189. InvivoGen Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 190. InvivoGen Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 191. InvivoGen Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 192. InvivoGen Main Business
Table 193. InvivoGen Latest Developments
Table 194. OZ Biosciences Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 195. OZ Biosciences Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 196. OZ Biosciences Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 197. OZ Biosciences Main Business
Table 198. OZ Biosciences Latest Developments
Table 199. Vaxine Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 200. Vaxine Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 201. Vaxine Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 202. Vaxine Main Business
Table 203. Vaxine Latest Developments
Table 204. Adjuvatis Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 205. Adjuvatis Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 206. Adjuvatis Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 207. Adjuvatis Main Business
Table 208. Adjuvatis Latest Developments
Table 209. Desert King Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 210. Desert King Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 211. Desert King Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 212. Desert King Main Business
Table 213. Desert King Latest Developments
Table 214. Sinovac Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 215. Sinovac Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 216. Sinovac Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 217. Sinovac Main Business
Table 218. Sinovac Latest Developments
Table 219. China National Biotec Group Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 220. China National Biotec Group Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 221. China National Biotec Group Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 222. China National Biotec Group Main Business
Table 223. China National Biotec Group Latest Developments
Table 224. Walvax Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 225. Walvax Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 226. Walvax Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 227. Walvax Main Business
Table 228. Walvax Latest Developments
Table 229. Anhui Zhifei Longcom Basic Information, Vaccine Particulate Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 230. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Product Portfolios and Specifications
Table 231. Anhui Zhifei Longcom Vaccine Particulate Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 232. Anhui Zhifei Longcom Main Business
Table 233. Anhui Zhifei Longcom Latest Developments
LIST OF FIGURES
Figure 1. Picture of Vaccine Particulate Adjuvants
Figure 2. Vaccine Particulate Adjuvants Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccine Particulate Adjuvants Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Vaccine Particulate Adjuvants Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Vaccine Particulate Adjuvants Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2025)
Figure 10. Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral
Figure 12. Product Picture of Subcutaneous
Figure 13. Product Picture of Intranasal
Figure 14. Product Picture of Intramuscular
Figure 15. Product Picture of Intradermal
Figure 16. Product Picture of Others
Figure 17. Global Vaccine Particulate Adjuvants Sales Market Share by Type in 2026
Figure 18. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026)
Figure 19. Product Picture of Mineral gel / precipitated particles
Figure 20. Product Picture of Liposomal vesicles
Figure 21. Product Picture of Virosomal vesicles
Figure 22. Product Picture of Saponin nanoparticle / ISCOM-type complexes
Figure 23. Product Picture of Polymeric micro- or nanoparticles
Figure 24. Product Picture of Others
Figure 25. Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture in 2026
Figure 26. Global Vaccine Particulate Adjuvants Revenue Market Share by Particle Architecture (2021-2026)
Figure 27. Product Picture of Aluminum salt-based particulate adjuvants
Figure 28. Product Picture of Phospholipid-based particulate adjuvants
Figure 29. Product Picture of Saponin-based particulate adjuvants
Figure 30. Product Picture of Polymer-based particulate adjuvants
Figure 31. Product Picture of Virus-membrane / virosome-based particulate adjuvants
Figure 32. Product Picture of Hybrid particulate systems
Figure 33. Product Picture of Others
Figure 34. Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition in 2026
Figure 35. Global Vaccine Particulate Adjuvants Revenue Market Share by Material Composition (2021-2026)
Figure 36. Product Picture of Surface-adsorbed particulate systems
Figure 37. Product Picture of Encapsulated particulate systems
Figure 38. Product Picture of Co-assembled particulate systems
Figure 39. Product Picture of Admixture particulate systems
Figure 40. Product Picture of Others
Figure 41. Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode in 2026
Figure 42. Global Vaccine Particulate Adjuvants Revenue Market Share by Antigen Association Mode (2021-2026)
Figure 43. Vaccine Particulate Adjuvants Consumed in Infectious Diseases
Figure 44. Global Vaccine Particulate Adjuvants Market: Infectious Diseases (2021-2026) & (K Units)
Figure 45. Vaccine Particulate Adjuvants Consumed in Cancer
Figure 46. Global Vaccine Particulate Adjuvants Market: Cancer (2021-2026) & (K Units)
Figure 47. Vaccine Particulate Adjuvants Consumed in Others
Figure 48. Global Vaccine Particulate Adjuvants Market: Others (2021-2026) & (K Units)
Figure 49. Global Vaccine Particulate Adjuvants Sale Market Share by Application (2025)
Figure 50. Global Vaccine Particulate Adjuvants Revenue Market Share by Application in 2025
Figure 51. Vaccine Particulate Adjuvants Sales by Company in 2025 (K Units)
Figure 52. Global Vaccine Particulate Adjuvants Sales Market Share by Company in 2025
Figure 53. Vaccine Particulate Adjuvants Revenue by Company in 2025 ($ millions)
Figure 54. Global Vaccine Particulate Adjuvants Revenue Market Share by Company in 2025
Figure 55. Global Vaccine Particulate Adjuvants Sales Market Share by Geographic Region (2021-2026)
Figure 56. Global Vaccine Particulate Adjuvants Revenue Market Share by Geographic Region in 2025
Figure 57. Americas Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 58. Americas Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 59. APAC Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 60. APAC Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 61. Europe Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 62. Europe Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 63. Middle East & Africa Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 64. Middle East & Africa Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 65. Americas Vaccine Particulate Adjuvants Sales Market Share by Country in 2025
Figure 66. Americas Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)
Figure 67. Americas Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 68. Americas Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 69. United States Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 70. Canada Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 71. Mexico Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 72. Brazil Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 73. APAC Vaccine Particulate Adjuvants Sales Market Share by Region in 2025
Figure 74. APAC Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2026)
Figure 75. APAC Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 76. APAC Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 77. China Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 78. Japan Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 79. South Korea Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 80. Southeast Asia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 81. India Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 82. Australia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 83. China Taiwan Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 84. Europe Vaccine Particulate Adjuvants Sales Market Share by Country in 2025
Figure 85. Europe Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)
Figure 86. Europe Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 87. Europe Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 88. Germany Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 89. France Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 90. UK Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 91. Italy Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 92. Russia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 93. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2026)
Figure 94. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 95. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 96. Egypt Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 97. South Africa Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 98. Israel Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 99. Turkey Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 100. GCC Countries Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 101. Manufacturing Cost Structure Analysis of Vaccine Particulate Adjuvants in 2026
Figure 102. Manufacturing Process Analysis of Vaccine Particulate Adjuvants
Figure 103. Industry Chain Structure of Vaccine Particulate Adjuvants
Figure 104. Channels of Distribution
Figure 105. Global Vaccine Particulate Adjuvants Sales Market Forecast by Region (2027-2032)
Figure 106. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Region (2027-2032)
Figure 107. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Type (2027-2032)
Figure 108. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Type (2027-2032)
Figure 109. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Application (2027-2032)
Figure 110. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Vaccine Particulate Adjuvants
Figure 2. Vaccine Particulate Adjuvants Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccine Particulate Adjuvants Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Vaccine Particulate Adjuvants Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Vaccine Particulate Adjuvants Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2025)
Figure 10. Vaccine Particulate Adjuvants Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral
Figure 12. Product Picture of Subcutaneous
Figure 13. Product Picture of Intranasal
Figure 14. Product Picture of Intramuscular
Figure 15. Product Picture of Intradermal
Figure 16. Product Picture of Others
Figure 17. Global Vaccine Particulate Adjuvants Sales Market Share by Type in 2026
Figure 18. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026)
Figure 19. Product Picture of Mineral gel / precipitated particles
Figure 20. Product Picture of Liposomal vesicles
Figure 21. Product Picture of Virosomal vesicles
Figure 22. Product Picture of Saponin nanoparticle / ISCOM-type complexes
Figure 23. Product Picture of Polymeric micro- or nanoparticles
Figure 24. Product Picture of Others
Figure 25. Global Vaccine Particulate Adjuvants Sales Market Share by Particle Architecture in 2026
Figure 26. Global Vaccine Particulate Adjuvants Revenue Market Share by Particle Architecture (2021-2026)
Figure 27. Product Picture of Aluminum salt-based particulate adjuvants
Figure 28. Product Picture of Phospholipid-based particulate adjuvants
Figure 29. Product Picture of Saponin-based particulate adjuvants
Figure 30. Product Picture of Polymer-based particulate adjuvants
Figure 31. Product Picture of Virus-membrane / virosome-based particulate adjuvants
Figure 32. Product Picture of Hybrid particulate systems
Figure 33. Product Picture of Others
Figure 34. Global Vaccine Particulate Adjuvants Sales Market Share by Material Composition in 2026
Figure 35. Global Vaccine Particulate Adjuvants Revenue Market Share by Material Composition (2021-2026)
Figure 36. Product Picture of Surface-adsorbed particulate systems
Figure 37. Product Picture of Encapsulated particulate systems
Figure 38. Product Picture of Co-assembled particulate systems
Figure 39. Product Picture of Admixture particulate systems
Figure 40. Product Picture of Others
Figure 41. Global Vaccine Particulate Adjuvants Sales Market Share by Antigen Association Mode in 2026
Figure 42. Global Vaccine Particulate Adjuvants Revenue Market Share by Antigen Association Mode (2021-2026)
Figure 43. Vaccine Particulate Adjuvants Consumed in Infectious Diseases
Figure 44. Global Vaccine Particulate Adjuvants Market: Infectious Diseases (2021-2026) & (K Units)
Figure 45. Vaccine Particulate Adjuvants Consumed in Cancer
Figure 46. Global Vaccine Particulate Adjuvants Market: Cancer (2021-2026) & (K Units)
Figure 47. Vaccine Particulate Adjuvants Consumed in Others
Figure 48. Global Vaccine Particulate Adjuvants Market: Others (2021-2026) & (K Units)
Figure 49. Global Vaccine Particulate Adjuvants Sale Market Share by Application (2025)
Figure 50. Global Vaccine Particulate Adjuvants Revenue Market Share by Application in 2025
Figure 51. Vaccine Particulate Adjuvants Sales by Company in 2025 (K Units)
Figure 52. Global Vaccine Particulate Adjuvants Sales Market Share by Company in 2025
Figure 53. Vaccine Particulate Adjuvants Revenue by Company in 2025 ($ millions)
Figure 54. Global Vaccine Particulate Adjuvants Revenue Market Share by Company in 2025
Figure 55. Global Vaccine Particulate Adjuvants Sales Market Share by Geographic Region (2021-2026)
Figure 56. Global Vaccine Particulate Adjuvants Revenue Market Share by Geographic Region in 2025
Figure 57. Americas Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 58. Americas Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 59. APAC Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 60. APAC Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 61. Europe Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 62. Europe Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 63. Middle East & Africa Vaccine Particulate Adjuvants Sales 2021-2026 (K Units)
Figure 64. Middle East & Africa Vaccine Particulate Adjuvants Revenue 2021-2026 ($ millions)
Figure 65. Americas Vaccine Particulate Adjuvants Sales Market Share by Country in 2025
Figure 66. Americas Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)
Figure 67. Americas Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 68. Americas Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 69. United States Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 70. Canada Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 71. Mexico Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 72. Brazil Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 73. APAC Vaccine Particulate Adjuvants Sales Market Share by Region in 2025
Figure 74. APAC Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2026)
Figure 75. APAC Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 76. APAC Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 77. China Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 78. Japan Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 79. South Korea Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 80. Southeast Asia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 81. India Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 82. Australia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 83. China Taiwan Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 84. Europe Vaccine Particulate Adjuvants Sales Market Share by Country in 2025
Figure 85. Europe Vaccine Particulate Adjuvants Revenue Market Share by Country (2021-2026)
Figure 86. Europe Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 87. Europe Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 88. Germany Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 89. France Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 90. UK Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 91. Italy Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 92. Russia Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 93. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2026)
Figure 94. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026)
Figure 95. Middle East & Africa Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026)
Figure 96. Egypt Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 97. South Africa Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 98. Israel Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 99. Turkey Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 100. GCC Countries Vaccine Particulate Adjuvants Revenue Growth 2021-2026 ($ millions)
Figure 101. Manufacturing Cost Structure Analysis of Vaccine Particulate Adjuvants in 2026
Figure 102. Manufacturing Process Analysis of Vaccine Particulate Adjuvants
Figure 103. Industry Chain Structure of Vaccine Particulate Adjuvants
Figure 104. Channels of Distribution
Figure 105. Global Vaccine Particulate Adjuvants Sales Market Forecast by Region (2027-2032)
Figure 106. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Region (2027-2032)
Figure 107. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Type (2027-2032)
Figure 108. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Type (2027-2032)
Figure 109. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Application (2027-2032)
Figure 110. Global Vaccine Particulate Adjuvants Revenue Market Share Forecast by Application (2027-2032)
